![]() ![]() ![]() associate Amy Feinberg and on benefits and compensation matters by Bay Area partner James Metz. associates Barrett Tenbarge, Alyssa Lattner and Julie Shin on tax matters by Bay Area partner Grace Lee, with Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. Advice was also provide on intellectual property matters by Bay Area/San Diego partner Christopher Hazuka, with San Diego associate Robert Yeh on regulatory matters by Washington, D.C. Latham & Watkins LLP represents the underwriters in the transaction with a life sciences capital markets team led by Bay Area partner Brian Cuneo, with Bay Area associates Phillip Stoup, Raul Gonzalez and Taimi Jacobson. In addition, Silverback has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. All of the shares are being offered by Silverback. The gross proceeds to Silverback from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$241.5 million. (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, has announced the pricing of its initial public offering of 11,500,000 shares of its common stock at a price to the public of US$21.00 per share. For more information please visit us at or contact your usual Swanson Reed representative.Silverback Therapeutics, Inc. Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. Fintel reports that Tanimoto Sarina has filed a 13D form with the SEC disclosing ownership of 6,265,170 shares of Silverback Therapeutics Inc (SBTX). We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes. Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test. you don’t need to have a patent to qualify). Less pain means less hesitation means less lives lost.Īre you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. The design of this EpiPen alternative would remove the need for needles, making administration less painful in a moment of panic. If the spray is approved, the company aims to launch the product in 2023. Food and Drug Administration by the third quarter of this year. ARS, which raised $55 million in a Series D round of funding last spring, plans to submit its NDA (new drug application) for neffy to the U.S. Silverback made a name for themselves for their experimental solid tumor therapy following a public offering in late 2020. The deal is expected to close in the fourth quarter of this year, pending stockholder approval. Silverback equity holders will own about 37% of the new company, and ARS’s 63%. The combined company is expected to have $265 million in cash, cash equivalents and marketable securities upon closing, including $240 million in cash from Silverback. If you wish to serve as lead plaintiff of the Silverback Therapeutics class action lawsuit, please provide your information by clicking here.You can also contact attorney J.C. The spray, called neffy, is a potential easy-to-use alternative to the EpiPen. ![]() The newly combined company will focus their expertise on regulatory approval and commercialization of ARS’s epinephrine nasal spray for severe allergic reactions. Going forward, the combined company will be called ARS Pharmaceuticals. ![]() ARS Pharmaceuticals has announced a merger with Silverback Therapeutics. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |